CClinicalTrials.gg
TerminatedNCT01059279Updated Apr 2, 2024

Heat Intolerance in the Group of FMF Patients

An observational study in Familial Mediterranean Fever, Heat Intolerance and Heat Tolerance Test, sponsored by Sheba Medical Center. Terminated at 1 site in Israel. Open to male participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by Sheba Medical Center · Observational

Why this study was terminated
unable to recruit patients
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
7
Ages
18 Years to 30 Years
Sex
Male
01

Study summary

There now causation between Heat Intolerance and FMF that were showed in studies till now. We suggest that the prevalence of Heat Intolerance in the group of the FMF patients will be significantly higher than in the group of healthy individuals, that participated in the study of Heller Institute of Medical Research. The aim of the study is verification of causation between these pathologies. The information obtained by the study may allow us to determine the sequence of events associated with FMF attack development, and perhaps take us one step further in the understanding of the pathogenesis of the disease.

15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30 without attacks during not less than 2 month will participate in the study. To identify an individuals susceptibility to exercise heat test, a Heat Tolerance Test (HTT) will perform, according to HTT Protocol of Heller Institute of Medical Research.

Read the detailed description

Familial Mediterranean fever (FMF) is a genetic disease, caused by mutations in the FMF gene, entitled MEFV. The disease is characterized by painful attacks of inflammation in sites lined by serous membranes (e.g. abdominal pain caused by inflammation of the peritoneum, a serous membrane surrounding all internal organs within the abdomen, fever during the attack. Continuous colchicine treatment prevents attacks in most patients. The pathogenesis of the disease, what leads to the attacks, is the questions not yet resolved. We know that there is correlation between protein Pyrin and activity of Interleukin 1 (IL1).

Tolerance to sustain heat stress varies due to individual variation. Under extreme conditions of exercise-heat stress, even healthy, well acclimated, physically fit individuals will ultimately store heat at the rate that will cause body temperature to rise. Individuals who are not able to sustain heat and whose body temperature will start rising earlier and at a higher rate than that of others, under the same conditions, are defined as "heat intolerant".

There now causation between Heat Intolerance and FMF that were showed in studies till now. We suggest that the prevalence of Heat Intolerance in the group of the FMF patients will be significantly higher than in the group of healthy individuals, that participated in the study of Heller Institute of Medical Research. The aim of the study is verification of causation between these pathologies. The information obtained by the study may allow us to determine the sequence of events associated with FMF attack development, and perhaps take us one step further in the understanding of the pathogenesis of the disease.

15 FMF patients with double mutations MEFV, male sex, from the age from 18 to 30 without attacks during not less than 2 month will participate in the study. To identify an individuals susceptibility to exercise heat test, a Heat Tolerance Test (HTT) will perform, according to HTT Protocol of Heller Institute of Medical Research.

02

Conditions studied

  • Familial Mediterranean Fever
  • Heat Intolerance
  • Heat Tolerance Test

Keywords

  • Familial Mediterranean fever
  • Cytokines
  • Inflammatory proteins
  • MEFV
  • mutations
  • Heat Intolerance
  • Heat Tolerance Test
03

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated with colchicine, without attacks not less than 2 months

Inclusion criteria

  • double mutations MEFV
  • mail
  • age from 18 to 30
  • colchicine treatment
  • absence of attack during 2 months

Exclusion criteria

Exclusion Criteria:

  • individual wish
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
7 participants (actual)

Groups and cohorts

  • FMF patients

    15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated with colchicine, without attacks not less than 2 months

  • healthy people

    Healthy individuals, that participated in the study of Heller Institute of Medical Research.

05

What researchers measure

Primary outcomes

  1. Rate of heat intolerance defined by the HTT protocol of Heller Institute of Medical Research.

    Number of patients who failed the HTT divided by number of patients undergoing the test. Failure to finished the test for reasons other than a rise in the temperature will be excluded

    Time frame: At the end of the test - One day test

06

Study locations

1 site
  • Sheba Medical Center
    Tel Hashomer., 52621, Israel
07

Registry details

Key details

Study ID
NCT01059279
Lead sponsor
Sheba Medical Center
Responsible party
Prof.Avi Livneh (Professor, Sheba Medical Center) — Principal investigator
First posted
Jan 29, 2010
Start date
Dec 2009
Primary completion
Aug 2012
Completion
Mar 3, 2024
Last update
Apr 2, 2024

Study contacts

Avi Livneh, MD
principal investigator · Sheba Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion